Hologic, Inc. (HOLX)

Market Cap	15.11B
Revenue (ttm)	4.04B
Net Income (ttm)	557.10M
Shares Out	222.42M
EPS (ttm)	2.41
PE Ratio	28.19
Forward PE	15.37
Dividend	n/a
Ex-Dividend Date	n/a

Volume	772,611
Open	68.00
Previous Close	67.93
Day's Range	67.67 - 68.34
52-Week Range	51.90 - 84.67
Beta	0.49
Analysts	Buy
Price Target	76.27 (+12.29%)
Earnings Date	Jul 30, 2025

About PETQ

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginos...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jun 21, 1990
• Employees: 7,063
• Stock Exchange: NASDAQ
• Ticker Symbol: HOLX
• Website: https://www.hologic.com

Financial Performance

In 2024, Hologic's revenue was $4.03 billion, a decrease of -0.00% compared to the previous year's $4.03 billion. Earnings were $789.50 million, an increase of 73.14%.

Analyst Summary

According to 13 analysts, the average rating for HOLX stock is "Buy." The 12-month stock price target is $76.27, which is an increase of 12.29% from the latest price.

Price Target

$76.27

(12.29% upside)

Analyst Consensus: Buy